Comparison of Metformin with Inositol Versus Metformin Alone in Women with Polycystic Ovary Syndrome: a Systematic Review and Meta-analysis of Randomized Controlled Trials

Overview

Journal Endocrine

Specialty Endocrinology

Date 2024 Sep 27

PMID 39331347

Authors

Francinny Alves Kelly

Artur de Oliveira Macena Lobo

Jorge Henrique Cavalcanti Orestes Cardoso

Francisco Cezar Aquino de Moraes

Affiliations

Soon will be listed here.

Abstract

Purpose: Metformin was the first medication targeting insulin resistance in PCOS, and it has been extensively studied as a metabolic treatment option. In recent years, inositols have emerged as potential treatment options for PCOS, but confidence in the available evidence supporting their use is limited.

Methods: We comprehensively searched PubMed, Embase, and Cochrane databases for RCTs comparing the use of combined metformin and inositol versus metformin alone in women with PCOS. A random-effects model was used to calculate the risk ratios (RRs) and mean differences (MDs) with 95% confidence intervals (CIs). A p-value of <0.05 was deemed as statistically significant.

Results: Six RCTs and 388 patients were included in the analysis, with follow-up ranging from 3 to 6 months. Combination therapy was significantly associated with improved menstrual cycle regularity (RR 1.56; 95% CI 1.01 to 2.41; p = 0.04), and lower values of modified Ferriman-Gallwey score (MD -0.97; 95% CI -1.53 to -0.40; p < 0.01) and LH/FSH ratios (MD -0.13; 95% CI -0.24 to -0.03; p = 0.01). Differences in acne (p = 0.58), body mass index (p = 0.13), fasting blood glucose (p = 0.07) and HOMA-IR (p = 0.25) were not statistically significant.

Conclusion: In this meta-analysis of RCTs, combination therapy was associated with cycle regularization and reduction in hirsutism and LH/FSH ratio compared to metformin monotherapy. Further studies are needed to clarify the true benefits of the use of inositol in PCOS treatment.

References

Choudhury A, Devi Rajeswari V . Polycystic ovary syndrome (PCOS) increases the risk of subsequent gestational diabetes mellitus (GDM): A novel therapeutic perspective. Life Sci. 2022; 310:121069. DOI: 10.1016/j.lfs.2022.121069. View

Dumitrescu R, Mehedintu C, Briceag I, Purcarea V, Hudita D . Metformin-clinical pharmacology in PCOs. J Med Life. 2015; 8(2):187-92. PMC: 4392089. View

Sharpe A, Morley L, Tang T, Norman R, Balen A . Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019; 12:CD013505. PMC: 6915832. DOI: 10.1002/14651858.CD013505. View

Garg D, Tal R . Inositol Treatment and ART Outcomes in Women with PCOS. Int J Endocrinol. 2016; 2016:1979654. PMC: 5067314. DOI: 10.1155/2016/1979654. View

Zeng L, Yang K . Effectiveness of myoinositol for polycystic ovary syndrome: a systematic review and meta-analysis. Endocrine. 2017; 59(1):30-38. DOI: 10.1007/s12020-017-1442-y. View

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

Ferriman D, GALLWEY J . Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21:1440-7. DOI: 10.1210/jcem-21-11-1440. View

Doshi A, Zaheer A, Stiller M . A comparison of current acne grading systems and proposal of a novel system. Int J Dermatol. 1997; 36(6):416-8. DOI: 10.1046/j.1365-4362.1997.00099.x. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

10.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

11.

Balduzzi S, Rucker G, Schwarzer G . How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019; 22(4):153-160. PMC: 10231495. DOI: 10.1136/ebmental-2019-300117. View

12.

Bahadur A, Arora H, Ravi A, Naithani M, Bahurupi Y, Chaturvedi J . Comparison of Clinical, Metabolic and Hormonal Effects of Metformin Versus Combined Therapy of Metformin With Myoinositol Plus D-Chiro-Inositol in Women With Polycystic Ovary Syndrome (PCOS): A Randomized Controlled Trial. Cureus. 2021; 13(6):e15510. PMC: 8263823. DOI: 10.7759/cureus.15510. View

13.

Chhabra N, Malik S . Effect of Insulin Sensitizers on Raised Serum Anti-mullerian Hormone Levels in Infertile Women with Polycystic Ovarian Syndrome. J Hum Reprod Sci. 2019; 11(4):348-352. PMC: 6333035. DOI: 10.4103/jhrs.JHRS_59_17. View

14.

Nazirudeen R, Sridhar S, Priyanka R, Sumathi B, Natarajan V, Subbiah E . A randomized controlled trial comparing myoinositol with metformin versus metformin monotherapy in polycystic ovary syndrome. Clin Endocrinol (Oxf). 2023; 99(2):198-205. DOI: 10.1111/cen.14931. View

15.

Witchel S, Oberfield S, Pena A . Polycystic Ovary Syndrome: Pathophysiology, Presentation, and Treatment With Emphasis on Adolescent Girls. J Endocr Soc. 2019; 3(8):1545-1573. PMC: 6676075. DOI: 10.1210/js.2019-00078. View

16.

Md Muslim M, Mohammed Jelani A, Shafii N, Yaacob N, Che Soh N, Ibrahim H . Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. J Ovarian Res. 2024; 17(1):106. PMC: 11102133. DOI: 10.1186/s13048-024-01436-x. View

17.

Diamanti-Kandarakis E, Dunaif A . Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012; 33(6):981-1030. PMC: 5393155. DOI: 10.1210/er.2011-1034. View

18.

Croze M, Soulage C . Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013; 95(10):1811-27. DOI: 10.1016/j.biochi.2013.05.011. View

19.

Eagle H, Oyama V, Levy M, Freeman A . Myo-Inositol as an essential growth factor for normal and malignant human cells in tissue culture. J Biol Chem. 1957; 226(1):191-205. View

20.

Zhao H, Xing C, Zhang J, He B . Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021; 18(1):171. PMC: 8371888. DOI: 10.1186/s12978-021-01207-7. View